Celyad (Formally Known as Cardio3 BioSciences)
Parc de L’Alliance
9, Boulevard de France
Braine - L’Alleud
134 articles with Celyad (Formally Known as Cardio3 BioSciences)
Celyad Oncology to announce full year 2022 financial results and host conference call
Celyad Oncology announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd.
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
Celyad Oncology announces the publication of the data from the haematological arm of the THINK study which evaluated CYAD-01 in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma patients.
Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property
Celyad Oncology, a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell therapies, provides an update on its Celyad 2.0 business strategy which has been adopted and implemented over the last few months.
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
Celyad Oncology SA provided an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2022.
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
Cellistic and Celyad Oncology announced a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel.
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
The FDA has placed a clinical hold on Beam Therapeutics' leukemia/lymphoma therapy and has lifted the hold on Celyad's CAR-T candidate for colorectal cancer.
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022.
Patient deaths associated with Astellas Pharma’s gene therapy candidate underscore the risks of developing potential one-and-done treatment options for serious diseases.
Belgium-based Celyad Oncology voluntarily paused a clinical trial with Merck after two deaths. Getting CAR T therapies to work in solid tumors has proven to be a difficult challenge.
Celyad announced that it is voluntarily pausing a clinical trial it’s conducting with Merck after reports of two patient deaths.
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
CEO to CEO: Tips for First-time Founders
1/11/2022BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders.
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.
Clinical Catch-Up: May 31-June 5
6/8/2020As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
BioSpace Movers & Shakers, June 5
6/5/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
BioSpace Movers & Shakers, May 8
5/8/2020Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace Movers & Shakers, March 6
3/6/2020Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week's Movers & Shakers.